Impax Announces Settlement of Contract Litigation on Opana® ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. DFTX

Go back to Impax Announces Settlement of Contract Litigation on Opana® ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets

Impax Laboratories (IPXL) PT Raised to $20 at Cowen Following Strong 2Q

August 9, 2017 1:54 PM EDT

Cowen raised its price target on Impax Laboratories (NASDAQ: IPXL) to $20.00 (from $12.00) while maintaining a Market Perform rating.

Impax reported 2Q results that were above expectations as total revenues of $202MM were $6MM above the Street's estimate. The better revenues and better... More